Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
burfiralimab
- Development stage
- Phase 2
- Lead developer
- ImmuneMed
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Burfiralimab is a humanized monoclonal antibody (IgG4) developed by ImmuneMed. It targets vimentin and acts as an immunomodulator and virus replication inhibitor. Burfiralimab is under clinical investigation for several indications including moderate to severe rheumatoid arthritis, chronic hepatitis B infection, and COVID-19 pneumonia. Its mechanism involves modulation of immune responses and inhibition of viral replication through binding to vimentin proteins[1][2][3][7]. Clinical trials have reached phase 2 for rheumatoid arthritis, hepatitis B, and COVID-19; phase 3 trials are ongoing or planned for severe COVID-19[6][8]. The drug is administered intravenously.
- Brand names
- hzVSF-v13hzVSF-v-13hzVSF-v 13
- Other names
- IMMUNOGLOBULIN G4, ANTI-(HUMAN VIMENTIN) (HUMAN-MUS MUSCULUS .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS .KAPPA.-CHAIN, dimer
02
Targets
VIM (Vimentin)
Beyond the preview
Go deeper on burfiralimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on burfiralimab.